Please assess the completion status of the following clinical trial:

Trial Title: Withdrawal Study to Demonstrate the Maintenance Effect in the Treatment of Non-24-Hour Sleep-Wake Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Ability and acceptance to provide informed consent;~2. Males, non-fecund females (i.e., surgically sterilized, if procedure was done 6 months before screening or subject is postmenopausal, without menses for 6 months before screening), or females of child-bearing potential using an acceptable method of birth control for a period of 35 days before the first dosing and must have a negative pregnancy test at the screening and baseline visits; Note: Women using hormonal methods of birth control must use an additional method of birth control during the study and for one month after the last dose.~3. Willing and able to comply with study requirements and restrictions including a commitment to a fixed 9-hour sleep opportunity during the study;~4. Diagnosis of N24HSWD in a previous clinical trial as measured by a tau value of \> 24.1 and the lower bound of the 95% CI is \> 24.~Exclusion Criteria:~1. History (within the 12 months prior to screening) of psychiatric disorders including Major Depressive Disorder, Generalized Anxiety Disorder, Axis II Disorders, delirium or any other psychiatric disorder, that is not being successfully treated or has not been resolved and that in the opinion of the clinical investigator would affect participation in the study or full compliance with study procedures;~2. History of intolerance and/or hypersensitivity to melatonin or melatonin agonists;~3. History of drug or alcohol abuse as defined in DSM-IV, Diagnostic Criteria for Drug and Alcohol Abuse, within the 12 months prior to screening and/or regular consumption of alcoholic drinks (\> 2 drinks/day or \> 14 drinks/week);~   a. Note: A standard drink is equal to 13.7 grams (0.6 ounces) of pure alcohol or~  * 12-ounces of beer~  * 8-ounces of malt liquor~  * 5-ounces of wine~  * 1.5-ounces or a shot of 80-proof distilled spirits or liquor (e.g., gin, rum, vodka, or whiskey);~4. Subject is at risk of suicide, in the opinion of the Investigator. Evidence of suicide risk could include any suicide attempt within the past year or any other suicidal behavior within the past year;~5. Current clinically significant cardiovascular, respiratory, neurologic, hepatic, hematopoietic, renal, gastrointestinal or metabolic dysfunction unless currently controlled and stable;~6. Subjects who have estimated creatinine clearance (CLcr; based on the Cockcroft-Gault equation) ≤ to 55 mL/min;~7. Clinically significant deviation from normal in clinical laboratory results, vital signs measurements, or physical examination findings at screening as determined by the clinical investigator;~8. Indication of impaired liver function (values for AST, ALT or bilirubin \> 2 times Upper Limit of Normal);~9. Pregnant or lactating females;~10. A positive test for drugs of abuse at the screening visit; Note: A positive drug screen at Visit 1 needs to be discussed with the medical monitor and will be evaluated on a case-by-case basis.~11. Smoke more than 10 cigarettes/day;~12. Worked night, rotating, or split (period of work, followed by break, and then return to work) shift work within 1 month of the screening visit or plan to work these shifts during the study;~13. Unwilling or unable to follow the medication restrictions described in Section 8.2., or unwilling or unable to sufficiently wash-out from use of a restricted medication~14. Unable to perform calls to the study IVR system to report questionnaire results;~15. Any other sound medical reason as determined by the clinical investigator;~16. Legal incompetence or limited legal competence, detainment in an institution for official or legal reasons.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- tasimelteon (Type: EXPERIMENTAL): 20 mg tasimelteon capsules
- Placebo (Type: PLACEBO_COMPARATOR): Placebo capsules

Based on this trial design, predict the completion outcome and termination type (if applicable).